Current Heart Failure Reports

, Volume 13, Issue 4, pp 190–195 | Cite as

Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?

  • Sylvia OleckEmail author
  • Hector O. Ventura
Pharmacologic Therapy (W H W Tang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pharmacologic Therapy


Heart failure affects 5.1 million people in the USA annually. It accounts for a frequent cause of hospitalizations and disability. Patients with congestive heart failure have lower plasma levels of CoQ10, which is an independent predictor of mortality in this patient population. It has been hypothesized that a deficiency of CoQ10 can play a role in the development and worsening of heart failure, and that oral supplementation can possibly improve symptoms and survival in these patients. Based on previous small studies and meta-analyses, the use of CoQ10 in heart failure suggested an improvement ejection fraction, stroke volume, cardiac output, and cardiac index with CoQ10 supplementation, however most of these small studies appeared to be underpowered to result in any significant data. The results of the recent Q-SYMBIO trial demonstrated an improvement in heart failure symptoms with a significant reduction in major adverse cardiovascular events and mortality.


Heart failure Coenzyme Q10 Ubiquinone Ubiquinol 


Compliance with Ethical Standards

Conflict of Interest

Sylvia Oleck and Hector O Ventura have no disclosures.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.CrossRefPubMedGoogle Scholar
  2. 2.
    DiNicolantonio J, Bhutani J, McCarty M, O’Keefe J. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2(1):e000326.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mantle D. Coenzyme Q10 and cardiovascular disease: an overview. October 2015. British J. Cardiology. 2015;22:160.CrossRefGoogle Scholar
  4. 4.
    Kapoor P, Kapoor AK. Coenzyme Q10—a novel molecule. J Indian Acad Clin Med. 2013;14:1.Google Scholar
  5. 5.
    Folkers K, Littarru GP, Ho L, et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch. 1970;40(3):380–90.PubMedGoogle Scholar
  6. 6.
    Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q 10. Proc Natl Acad Sci U S A. 1985;82:901–4.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:1435–4. Langsjoen, P. Alleviating Congestive Heart Failure with Coenzyme Q10. LE Magazine Febuary 2008.CrossRefPubMedGoogle Scholar
  8. 8.
    Rauchova H, Lenaz G, Drahota Z. Function of coenzyme Q in the Cekk: some biochemical and physiological properties. Physiol Res. 1995;44:209–16.PubMedGoogle Scholar
  9. 9.
    Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;39(6):957–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. 2014;6:CD008684.PubMedGoogle Scholar
  11. 11.
    Langsjoen P. Alleviating congestive heart failure with coenzyme Q10. LE magazine. 2008.Google Scholar
  12. 12.
    Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82(12):4240–4.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169–71.PubMedGoogle Scholar
  14. 14.
    Oda T. Effect of coenzyme Q10 on load-induced cardiac dysfunction: double-blind study and investigation of dose-response relationship. In: Lenaz G, Barnabei O, Rabbi A, editors. Highlights in ubiquinone research. Taylor and francis: London; 1990. p. 232–7.Google Scholar
  15. 15.
    Rossi E, Lombardo A, Testa M, Lippa S, Oradei A, Littarru GP, et al. Coenzyme Q10 in ischaemic cardiopathy. In: Folkers K, Yamagami T, Littarru GP, editors. Biomedical and clinical aspects of coenzyme Q, vol. 6. Amsterdam: Elsevier; 1991. p. 321–6.Google Scholar
  16. 16.
    Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy: a medium-term randomized double-blind study versus placebo. Curr Ther Res. 1991;49:878–86.Google Scholar
  17. 17.
    Rengo F, Abete P, Landino P, et al. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71:S124–S8.CrossRefPubMedGoogle Scholar
  18. 18.
    Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q 10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail. 1995;1:101–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors. 1999;9(2-4):285–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Asp Med. 1994;15:s155–163.CrossRefGoogle Scholar
  21. 21.
    Judy W, Hall J, Toth P, et al. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru G, Yamagami T, editors. Biomedical and clinical aspects of coenzyme Q, vol. 6. Amsterdam: Elsevier, Publishers; 1991. p. 291–8.Google Scholar
  22. 22.
    Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;65(7):521–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Judy W, Hall J, Toth P, et al. Double blind-double crossover study of coenzyme Q10 in heart failure. Biomed Clin Aspects Coenzyme Q. 1986;5:315–23.Google Scholar
  24. 24.
    VanFraechem JPH, Picalausa C, Folkers K. Ef—fects of CoQ10 on physical performance and recovery in myo- cardial failure. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q, vol. 5. Amsterdam: Elsevier Publishers; 1986. p. 377.Google Scholar
  25. 25.
    Schneeberger W, Muller-Steinwachs J, Anda L, et al. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q, vol. 5. Amsterdam: Elsevier; 1986. p. 325–33.Google Scholar
  26. 26.
    Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multi-center randomized study. Clin Investig. 1993;71:S134–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Permanetter B, Rössy W, Klein G, Weingartner F, Seidl KF, Blömer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13(11):1528–33.PubMedGoogle Scholar
  28. 28.
    Watson PS, Scalia GM, Gaibraith AJ, Burstow DJ, Aroney CN, Bett JH. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 2001;175(8):447. author reply 447-8.PubMedGoogle Scholar
  29. 29.
    Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132(8):636–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Soja AM, Mortenson SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18:159–68.CrossRefGoogle Scholar
  31. 31.
    Sander CCI, Patel AA, et al. The impact of coenzyme q10 on systolic function in patients with chronic heart failure. J Card Failure. 2006;12:464–72.CrossRefGoogle Scholar
  32. 32.
    Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr. 2013;97:268–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G, Kocharian A, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young. 2009;19(5):501–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27(5):295–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation. 2003;12(3):135–41.CrossRefPubMedGoogle Scholar
  37. 37.
    2013 ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239Google Scholar
  38. 38.
    Mortensen S, Kumar A, Filipiak K, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. Eur J Heart Fail. 2013;15(S1):S20.Google Scholar
  39. 39.
    Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2:641–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Langsjoen PHm Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors. 2008;32(1-4):119–28.CrossRefGoogle Scholar
  41. 41.
    Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. Study on safety and bioavailability of ubiquinol (Kaneka QH (trade mark)) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007;47(1):19–28.CrossRefPubMedGoogle Scholar
  42. 42.
    Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273–84.CrossRefPubMedGoogle Scholar
  43. 43.
    Mortensen SA. Coenzyme Q10: will this natural substance become a guideline-directed adjunctive therapy in heart failure? JCHF. 2015;3(3):270–1.Google Scholar
  44. 44.
    Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27(22):2675–81.CrossRefPubMedGoogle Scholar
  45. 45.
    Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007;28(18):2249–55.CrossRefPubMedGoogle Scholar
  46. 46.
    Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001;94(11):1112–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009;4, CD007435.PubMedGoogle Scholar
  48. 48.
    Caso G et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12.CrossRefPubMedGoogle Scholar
  49. 49.
    Marcoff L, Thompson P. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. JACC. 2007;49(23):2231–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94(10):1306–10.CrossRefPubMedGoogle Scholar
  52. 52.
    Our History Timeline.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Cardiovascular Diseases, John Ochsner Heart and Vascular InstituteOchsner Clinical School-University of Queensland School of MedicineNew OrleansUSA
  2. 2.Department of CardiologyNew OrleansUSA

Personalised recommendations